公开(公告)号：US20230250087A1

公开(公告)日：2023-08-10

申请号：US18001371

申请日：2021-06-11

申请人： VERTEX PHARMACEUTICALS INCORPORATED

发明人： Kevin James GAGNON ,  Jicong LI ,  Ales MEDEK ,  Jack Raphael MINCHOM ,  Yi SHI ,  Muna SHRESTHA ,  Faith WITKOS

IPC分类号： C07D403/12

CPC分类号： C07D403/12 ,  C07B2200/13

摘要： The disclosure provides novel solid state forms of Compound I selected from ethanol solvate Form A, ethanol solvate Form B, citric acid cocrystal Form A, and Form B, compositions comprising the same, and methods of making and using the same, including use in treating APOL1 mediated kidney disease. (I).

公开(公告)号：US20210246121A1

公开(公告)日：2021-08-12

申请号：US17166927

申请日：2021-02-03

申请人： Vertex Pharmaceuticals Incorporated

发明人： Mei-Hsiu LAI ,  Jicong LI ,  Muna SHRESTHA ,  Ales MEDEK ,  Yi SHI ,  Andrey PERESYPKIN ,  Michael JUDELSON ,  Jack MINCHOM ,  Courtney MAGUIRE ,  Kevin GAGNON ,  Faith WITKOS ,  Satish Kumar IYEMPERUMAL ,  Kanika SARPAL

IPC分类号： C07D403/12

摘要： The disclosure provides novel solid state forms of Compound I selected from Form B, citric acid cocrystal Form A, piperazine cocrystal Form A, urea cocrystal Form A, nicotinamide cocrystal Form A, nicotinamide cocrystal Form B, aspartame cocrystal Form A, glutaric acid cocrystal Form A, L-proline cocrystal Form A, L-proline cocrystal Form B, vanillin cocrystal Form A, and 2-pyridone cocrystal Form A, compositions comprising the same, and methods of using the same, including use in treating APOL1 mediated kidney disease.